Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Cognitive dysfunction is a significant challenge in schizophrenia (SCZ) treatment.
• Aripiprazole (ARI) shows some cognitive benefits, but its efficacy is limited.
• Nerve growth factor (NGF) has potential for cognitive enhancement, yet its role in SCZ is unclear.

Purpose of the Study:

• To investigate the therapeutic potential of ARI combined with NGF for cognitive dysfunction in a schizophrenia mouse model.
• To elucidate the underlying mechanisms involving brain-derived neurotrophic factor (BDNF).

Main Methods:

• Schizophrenia mouse model induced by dizocilpine (MK-801).
• Treatment groups: ARI alone, NGF alone, ARI + NGF combination.
• Assessment of spontaneous activity and cognitive function (open field test, Morris water maze).
• Measurement of BDNF protein and mRNA levels in the prefrontal cortex (PFC) and hippocampus (HIP).

Main Results:

• Both ARI alone and ARI + NGF combination improved spontaneous activity and spatial learning memory deficits in model mice.
• Treatment elevated BDNF expression levels in the PFC and HIP.
• The combination therapy demonstrated enhanced efficacy compared to ARI alone.

Conclusions:

• ARI combined with NGF effectively improves cognitive function in a schizophrenia mouse model.
• The therapeutic benefits are associated with increased BDNF levels in key brain regions.
• This combination therapy presents a promising new strategy for treating cognitive dysfunction in SCZ.